1. Home
  2. IOVA vs NPO Comparison

IOVA vs NPO Comparison

Compare IOVA & NPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOVA
  • NPO
  • Stock Information
  • Founded
  • IOVA 2007
  • NPO 2002
  • Country
  • IOVA United States
  • NPO United States
  • Employees
  • IOVA N/A
  • NPO N/A
  • Industry
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • NPO Metal Fabrications
  • Sector
  • IOVA Health Care
  • NPO Industrials
  • Exchange
  • IOVA Nasdaq
  • NPO Nasdaq
  • Market Cap
  • IOVA 3.0B
  • NPO 3.4B
  • IPO Year
  • IOVA N/A
  • NPO N/A
  • Fundamental
  • Price
  • IOVA $8.18
  • NPO $165.81
  • Analyst Decision
  • IOVA Strong Buy
  • NPO
  • Analyst Count
  • IOVA 9
  • NPO 0
  • Target Price
  • IOVA $23.33
  • NPO N/A
  • AVG Volume (30 Days)
  • IOVA 7.2M
  • NPO 104.2K
  • Earning Date
  • IOVA 11-07-2024
  • NPO 11-05-2024
  • Dividend Yield
  • IOVA N/A
  • NPO 0.73%
  • EPS Growth
  • IOVA N/A
  • NPO N/A
  • EPS
  • IOVA N/A
  • NPO 2.56
  • Revenue
  • IOVA $90,858,000.00
  • NPO $1,039,400,000.00
  • Revenue This Year
  • IOVA $13,827.67
  • NPO N/A
  • Revenue Next Year
  • IOVA $183.70
  • NPO $3.43
  • P/E Ratio
  • IOVA N/A
  • NPO $63.82
  • Revenue Growth
  • IOVA 12751.20
  • NPO N/A
  • 52 Week Low
  • IOVA $4.44
  • NPO $123.56
  • 52 Week High
  • IOVA $18.33
  • NPO $176.13
  • Technical
  • Relative Strength Index (RSI)
  • IOVA 32.59
  • NPO 63.20
  • Support Level
  • IOVA $9.31
  • NPO $161.36
  • Resistance Level
  • IOVA $10.86
  • NPO $167.41
  • Average True Range (ATR)
  • IOVA 0.71
  • NPO 4.66
  • MACD
  • IOVA -0.37
  • NPO 1.57
  • Stochastic Oscillator
  • IOVA 1.48
  • NPO 84.46

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About NPO Enpro Inc.

Enpro Inc formerly EnPro Industries Inc is a United States-based company that designs, develops, manufactures, and markets proprietary engineered industrial products. The company operates through three segments: Sealing Technologies, which manufactures and markets sealing products, wheel-end components & systems, and Advanced Surface Technologies manufactures wafer processing sub-systems, thin-film coatings, optical filters, and other services like cleaning, coating, testing, and refurbishment. Its geographical segments are the United States, Europe, and other foreign countries.

Share on Social Networks: